A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas

Trial Profile

A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs CPI 1205 (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Constellation Pharmaceuticals
  • Most Recent Events

    • 07 Mar 2018 Results presented at the 16th International Congress on Targeted Anticancer Therapies
    • 02 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 22 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top